Embryo and genetic screening are crucial parts of modern IVF (In Vitro Fertilization) treatments. These methods aim to identify genetic or chromosomal abnormalities in embryos before they are implanted into the uterus.
While they help improve success rates and reduce the risk of hereditary disorders, defects in screening technology or process errors can sometimes lead to misdiagnosis, embryo rejection, or failed pregnancies.
Preimplantation Genetic Testing (PGT)
PGT is a laboratory process where cells from an embryo are tested before implantation.
It includes several types:
- PGTA (Preimplantation Genetic Testing for Aneuploidy): Detects abnormal chromosome numbers that may cause miscarriage or developmental defects.
- PGTM (Preimplantation Genetic Testing for Monogenic Disorders): Identifies single-gene diseases like cystic fibrosis or thalassemia.
- PGTSR (Preimplantation Genetic Testing for Structural Rearrangements): Checks chromosome translocations or deletions.
However, defects can occur due to:
- Sampling errors: Incorrect or damaged biopsy samples.
- False positives/negatives: Healthy embryos may be misclassified as defective or vice versa.
- Embryo mosaicism: When different cells in the same embryo have different chromosomes, it can confuse test accuracy.
Defects And Limitations
Even advanced testing technologies have biological and technical limitations:
- False Diagnosis: Some healthy embryos may be discarded unnecessarily.
- Embryo Damage: During biopsy, removing cells can harm embryo viability.
- Technology Error: Faulty equipment, lab contamination, or data interpretation mistakes.
- Incomplete Detection: Not all genetic disorders can be detected — some appear later during development or after birth.
These screening defects not only cause emotional and financial distress but may also lead to ethical and legal disputes between patients and clinics.
Ethical Concerns
Genetic screening introduces deep ethical debates:
- Designer Baby Risk: Using genetics to select non-medical traits (like gender or appearance).
- Embryo Disposal Ethics: What happens to embryos labeled “defective”?
- Data Privacy: Sensitive genetic data of embryos and parents needs strict protection.
Such concerns raise questions about how far science should go in selecting human traits.
Impact On Women
Women undergoing IVF face both physical and emotional impacts due to genetic screening outcomes:
- Stress from waiting for results or losing viable embryos.
- Repeated IVF cycles due to mis-classification.
- Guilt or anxiety linked to “genetic defects” in embryos.
- Legal and ethical dilemmas when clinics mishandle samples.
These highlight that defects in embryo screening don’t just affect embryos — they also deeply affect women’s mental and reproductive health.
Future Trends
Research is now moving toward non-invasive genetic testing, analysing DNA from the embryo’s surrounding culture medium rather than biopsy — reducing risk of damage.
Other innovations include:
- AI-based Embryo Selection (AI In IVF): Machine learning to predict success rates.
- Whole-genome sequencing: For comprehensive defect detection.
- Microfluidics: For gentle, automated embryo handling.
While promising, these also need regulation to prevent new types of diagnostic defects.
Conclusion
Embryo / Genetic Screening has revolutionised IVF success, but its own defects — biological, technical, and ethical — must be managed carefully.
Stronger regulations, transparency, and patient awareness can ensure these technologies truly serve women safely and effectively.